文献速递心律失常心力衰竭与心肌病

FLNC截短变异携带者的心律失常风险分层

Arrhythmic Risk Stratification of Carriers of Filamin C Truncating Variants.
PubMed 文献 · JAMA Cardiol · 2025-01-01

该国际多中心回顾性队列研究纳入308例致病或可能致病性FLNC截短变异携带者,随访中位34个月,19%发生心源性猝死或重大室性心律失常,年发生率4例/100人年。多变量模型显示年龄、男性、晕厥史、非持续性室速和左室射血分数可预测风险,AUC为0.76-0.78。

要点

  • FLNCtv携带者SCD/MVA年发生率为4例/100人年,表型阳性者风险更高。
  • 五变量模型(年龄、男性、晕厥、NSVT、LVEF)可估风险,AUC 0.76-0.78。
  • LVEF>58%时风险显著降低,LVEF<58%时风险不随LVEF下降而增加。

核心结论

  • 表型阳性FLNCtv携带者SCD/MVA风险高,五变量模型可辅助预防性ICD植入的共享决策。

研究设计与样本

  • 国际多中心回顾性队列研究,纳入19个转诊中心308例致病或可能致病性FLNCtv携带者,中位年龄45岁,男性52%。

主要发现

  • 中位随访34个月,57例(19%)发生SCD/MVA,年发生率4例/100人年(95%CI 3-6)。
  • 先证者较非先证者、表型阳性较表型阴性者发生率更高。
  • 预测模型含年龄、男性、既往晕厥、非持续性室速和LVEF,时间依赖AUC 12个月0.76(95%CI 0.67-0.86),72个月0.78(95%CI 0.70-0.86)。
  • LVEF与SCD/MVA风险关联非线性,LVEF>58%时风险显著更低,LVEF<58%时无增加。
  • Bootstrap内部验证显示模型准确度和校准良好,亚组分析结果一致。

关键数值与推荐

  • 表型阴性定义为12导联心电图、动态心电图、超声心动图和心脏磁共振均无病理发现。
  • 主要终点为SCD/MVA复合终点,MVA包括复苏的SCD、持续性室速和适当的ICD干预。

临床怎么用

  • 对FLNCtv携带者,尤其表型阳性者,应评估年龄、性别、晕厥史、NSVT和LVEF以进行风险分层。
  • 预测模型可用于辅助预防性ICD植入的共享决策,但需外部队列验证。

局限性

  • 回顾性队列设计。
  • 需外部队列验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Filamin C truncating variants (FLNCtv) are a rare cause of cardiomyopathy with heterogeneous phenotypic presentations. Despite a high incidence of life-threatening ventricular arrhythmias and sudden cardiac death (SCD), reliable risk predictors to stratify carriers of FLNCtv are lacking. OBJECTIVE: To determine factors predictive of SCD/major ventricular arrhythmias (MVA) in carriers of FLNCtv. DESIGN, SETTING, AND PARTICIPANTS: This was an international, multicenter, retrospective cohort study conducted from February 2023 to June 2024. The Filamin C Registry Consortium included 19 referral centers for genetic cardiomyopathies worldwide. Participants included carriers of pathogenic or likely pathogenic FLNCtv. Phenotype negative was defined as the absence of any pathological findings detected by 12-lead electrocardiogram (ECG), Holter ECG monitoring, echocardiography, or cardiac magnetic resonance. EXPOSURES: Composite of SCD and MVA in carriers of FLNCtv. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of SCD and MVA, the last including aborted SCD, sustained ventricular tachycardia, and appropriate implantable cardioverter-defibrillator (ICD) interventions. RESULTS: Among 308 individuals (median [IQR] age, 45 [33-56] years; 160 male [52%]) with FLNCtv, 112 (36%) were probands, and 72 (23%) were phenotype negative. Median (IQR) left ventricular ejection fraction (LVEF) was 51% (38%-59%); 89 participants (34%) had LVEF less than 45%, and 50 (20%) had right ventricular dysfunction. During a median (IQR) follow-up of 34 (8-63) months, 57 individuals (19%) experienced SCD/MVA, with an annual incidence rate of 4 cases per 100 person-years (95% CI, 3-6). Incidence rates were higher in probands vs nonprobands and in phenotype-positive vs phenotype-negative individuals. A predictive model estimating SCD/MVA risk was derived from multivariable analysis, which included older age, male sex, previous syncope, nonsustained ventricular tachycardia, and LVEF with a time-dependent area under the curve (AUC) ranging between 0.76 (95% CI, 0.67-0.86) at 12 months and 0.78 (95% CI, 0.70-0.86) at 72 months. Notably, the association of LVEF with the SCD/MVA risk was not linear, showing significant lower risk for values of LVEF greater than 58%, and no increase for values less than 58%. Internal validation with bootstrapping confirmed good accuracy and calibration of the model. Results were consistent in subgroups analysis (ie, phenotype-positive carriers and phenotype-positive carriers without MVA at onset). CONCLUSIONS AND RELEVANCE: Results suggest that the risk of SCD/MVA in phenotype-positive carriers of FLNCtv was high. A 5-variable predictive model derived from this cohort allows risk estimation and could support clinicians in the shared decision for prophylactic ICD implantation. External cohort validation is warranted.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Gigli M, Stolfo D, Barbati G, et al. Arrhythmic Risk Stratification of Carriers of Filamin C Truncating Variants. JAMA Cardiol. 2025. PMID: 39937464. doi:10.1001/jamacardio.2024.5543

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。